Due to the involvement of SHP2 (SH2 domain-containing protein tyrosine phosphatase) in human 17 disease, including Noonan syndrome and cancer, several inhibitors targeting SHP2 have been 18 developed. Here, we report that the commonly used SHP2 inhibitor NSC-87877 does not exhibit 19 robust inhibitory effects on growth factor-dependent MAPK (mitogen-activated protein kinase) 20 pathway activation, and that the recently developed active site-targeting SHP2 inhibitors IIB-08, 21 11a-1, and GS-493 show off-target effects on ligand-evoked activation/trans-phosphorylation of the 22 PDGFR (platelet-derived growth factor receptor ). GS-493 also inhibits purified human PDGFR 23 and SRC in vitro, whereas PDGFR inhibition by IIB-08 and 11a-1 occurs only in the cellular 24 context. Our results argue for extreme caution in inferring specific functions for SHP2 based on 25 studies using these inhibitors. 26 27 28 Key Words 29 SHP2 inhibitor, NSC-87877, GS-493, IIB-08, 11a-1, PDGFR 30 31 32 Abbreviations 33 4-OHT, 4-hydroxytamoxifen; EGF, epidermal growth factor; MAPK, mitogen-activated protein 34 kinase; PDGF, platelet-derived growth factor; PDGFRplatelet-derived growth factor receptor ; 35 PTPprotein-tyrosine phosphatase; PTK, protein-tyrosine kinase;. pY, phosphotyrosyl; RTK, 36 receptor tyrosine kinase; SHP2, SH2 domain-containing protein-tyrosine phosphatase. 37
Introduction 39
SHP2, encoded by PTPN11, is a classic protein-tyrosine phosphatase (PTP), comprising 40 two tandem SH2 domains (N-SH2 and C-SH2, respectively), followed by a catalytic (PTP) domain 41 and a C-terminal tail [1] . In the absence of appropriate cellular stimuli, SHP2 resides in an 42 auto-inhibitory "closed" structure, as a consequence of intra-molecular interactions between the 43 N-SH2 and PTP domains [2] . Upon stimulation of cells with appropriate growth factors, such as 44 platelet-derived growth factor (PDGF) or epidermal growth factor (EGF), the cognate receptor 45 tyrosine kinase (RTK) is activated, resulting in receptor trans-phosphorylation [3, 4] , as well as 46 phosphorylation of scaffolding proteins, such as GAB family members [5] . SHP2 binds to 47 phosphorylated RTKs and/or scaffold proteins via SH2 domain/phosphotyrosyl (pY) interactions, 48 which are incompatible with intra-molecular N-SH2/PTP interaction and result in an enzymatically 49 activated "open" structure [1, 2] . 50
Once activated, SHP2 functions as a key positive regulator of RTK-evoked signal 51 transduction, acting upstream of RAS in the ERK MAP kinase pathway [6, 7] . Phosphatase activity 52 is required for SHP2 action [8] , although the key substrate(s) remain controversial. In addition, in 53 response to most agonists, SHP2 itself undergoes tyrosyl phosphorylation on two C-terminal 54 tyrosines, which then function as GRB2 binding sites. This "adapter" function for SHP2 enhances 55 RAS/ERK signaling [9] . 56
Mutations that affect residues at the N-SH2/PTP interface of SHP2 cause aberrant 57 enzymatic activation, due to inability to form the "closed" structure. Such mutations are found 58 frequently in, and are responsible for, several disorders, including Noonan syndrome [10] , juvenile 59 myelomonocytic leukemia (JMML) [1, 11, 12] , and, less frequently, solid tumors such as 60 neuroblastoma [13] . In addition, SHP2, along with its binding partner GAB2, is required for 61 BCR/ABL-evoked transformation and leukemogenesis [1, 14] However, potential off-target effects of these molecules against other enzyme families (e.g., kinases) 73 have, in general, not been reported. 74
We tested the effects of the commonly used active site SHP2 inhibitors, NSC-87877, 75 IIB-08, 11a-1, and GS-493 on PDGF signaling in fibroblasts, and found that they either failed to 76 effectively inhibit SHP2 function in cells (NSC-87877) or had off-target effects on protein-tyrosine 77 kinases (PTKs). These results argue strongly that such agents cannot be used alone to infer SHP2 78 functions in health or disease. 
Expression Constructs, Infection and Sorting 106
Retroviral expression vectors for wild type SHP2 (WT SHP2) and the mutant SHP2 C459E 107 were generated by sub-cloning human PTPN11 cDNA into pMSCV-IRES-EGFP (Clontech). 108
Ptpn11 fl/fl MEFs expressing WT or mutant SHP2 were generated by retroviral infection, according to 109 the manufacturer's protocol (pMSCV retrovirus system, Clontech,) followed by fluorescence Starved cells were then stimulated with PDGF-BB (50 ng/ml, final concentration) or EGF (1 ng/ml 117 or 50 ng/ml, final concentration) as indicated. For inhibitor treatment, cells were pre-incubated for 3 118 h (NSC-87877) or 30 min (other SHP2 inhibitors) in media (1 ml/well) containing the indicated 119 concentrations of each compound with 0.5% DMSO or 0.5% DMSO alone, followed by addition of 120 10 l of medium containing 5 g/ml PDGF-BB (50 ng/ml, final concentration). Cells were lysed in 121 SDS lysis buffer (50 mM Tris-HCl pH7.5, 100 mM NaCl, 1 mM EDTA, 1% SDS, 2 mM Na 3 VO 4 ). 122
Lysates were resolved by SDS-PAGE, followed by transfer to Immobilon-FL PVDF membranes 123 (Millipore). Membranes were blocked in 1% BSA/TBS containing 0.1% Tween20 for 30 min, and 124 treated with primary antibodies in blocking buffer for 1 h, followed by treatment with 125
IRDye-conjugated secondary antibodies (LI-COR). Images were obtained by using an ODYSSEY 126 [7]. MEFs were reconstituted with wild type (WT) SHP2 or a catalytically inactive SHP2 mutant 149 (C459E), and then were treated with 4-OHT (1 M) for 4 days to delete endogenous Ptpn11. Upon 150 PDGF-BB-treatment (50 ng/ml) after serum-starvation, parental (undeleted) cells showed 151 agonist-evoked phosphorylation/activation of the ERK MAPK pathway components, MEK1 and 152 ERK1/2, whereas these were strongly suppressed by SHP2 depletion (Fig. 1) . Suppressed ERK 153 signaling in Ptpn11 knockout cells was rescued by re-expression of WT SHP2, but not by SHP2 C459E 154 ( Fig. 1) , confirming a requirement for SHP2 catalytic activity in PDGFR-induced ERK activation in 155 fibroblasts. Notably, overall PDGFR tyrosyl phosphorylation, as well as phosphorylation of multiple 156 specific PDGFR tyrosyl residues (pY579, pY716, pY857 and pY1009 of PDGFR were 157 unaffected, or slightly increased, by the absence of catalytically active SHP2 in Ptpn11-knockout 158 cells (Fig. 1) . These data indicate that SHP2 does not enhance (and might inhibit some) PDGFR 159 tyrosyl phosphorylation events (at these time points) in this immortalized MEF line. 160 161
Active site-targeting SHP2 inhibitors suppress PDGF-evoked ERK activation and 162

PDGFR-phosphorylation 163
We then tested the effects of the active site-targeting SHP2 inhibitors, NSC-87877, IIB-08, ERK MAPK signaling ( Fig. 2A) . We also failed to reproduce reported inhibitory effects of this 169 compound on EGF (1ng/ml or 50 ng/ml)-stimulated ERK activation in HEK293T cells [20] (Fig.  170   2B) . By contrast, the allosteric SHP2 inhibitor SHP099 effectively suppressed PDGF-or EGF-stimulated ERK MAPK pathway in Swiss 3T3 cells or HEK293T cells, respectively (Fig. 2C) . 172
The other active site inhibitors tested efficiently abolished PDGF-evoked MEK1 173 phosphorylation, but also strongly suppressed ligand-dependent tyrosine phosphorylation of 174 PDGFR (Fig. 2D ). As Ptpn11 knockout (Fig. 1 ) did not attenuate PDGFR phosphorylation, we 175 tested these inhibitors in MEFs. In contrast to the effects of SHP2 depletion or replacement of SHP2 176 with a catalytically inactive SHP2 mutant, IIB-08, 11a-1, and GS-493 suppressed ligand-dependent 177 PDGFR phosphorylation in wild type MEFs. Even more importantly, these inhibitors also blocked 178 PDGFR phosphorylation in cells lacking SHP2 ( Fig. 2E) . By contrast, treatment of MEFs with 179 SHP099 suppressed PDGF-dependent MEK/ERK activation without suppressing PDGFR 180 phosphorylation (Fig. 2F) . These observations show unambiguously that suppression of PDGFR 181 phosphorylation by these active site inhibitors is independent of SHP2, and indicate that they have 182 off-target effects, at least in fibroblasts. 183 184
GS-493, but not IIB-08 and 11a-1, inhibits PDGFR and SRC kinase activities in vitro. 185
To investigate how IIB-08, 11a-1, and GS-493 block PDGFR tyrosine phosphorylation, 186
we first asked whether they directly inhibit PDGFR kinase activity in vitro. Indeed, GS-493 187 inhibited the purified PDGFR kinase domain (IC 50 =1.6 M), and also inhibited recombinant SRC 188 (IC 50 =746 nM). By contrast, IIB-08 or 11a-1 did not significantly inhibit either isolated kinase 189 domain in vitro. inhibition. Nevertheless, these inhibitors have been used extensively to probe SHP2 action (reviewed 208 in refs. 26, 27), often as major perturbants of SHP2 function. By contrast, the allosteric inhibitor 209 SHP099 does not have off-target effects on SRC or other tyrosine kinases in vitro [24] or in the 210 cellular contexts described here. Even so, comparing the effects of SHP099 and SHP2 depletion (via 211 chemical degradation) indicates that SHP099 also can have off-target effects in at least some settings 212
[28]. 213
In summary, the above study and our results indicate that reports using SHP2 inhibitors as 214 the major means of inferring SHP2 function must be re-evaluated and potentially re-interpreted. For 215 SHP099-like compounds, defined drug-resistant mutants can be used in rescue experiments to 216 demonstrate specificity [24] . Current allosteric SHP2 inhibitors act as "molecular glue" stabilizing 217 the closed, inactive form of the enzyme, and thereby act like "chemical nulls" that potentially block 218 multiple, if not all, aspects of SHP2 function [29] . For this reason, it would certainly be useful to 219 have validated "on-target" catalytic inhibitors. The off-target effects revealed here argue that 220 additional efforts are necessary to achieve this goal, and emphasize the need for careful control 221 experiments and multiple lines of evidence to confidently assign functions to SHP2 using inhibitor 222 approaches. 223 activities of purified human PDGFR or human SRC in vitro were measured in the presence of serial 328 dilutions of IIB-08, 11a-1, or GS-493. Graphs show relative inhibition of kinase activity in the 329 presence of indicated concentration of each inhibitor (averages of duplicates, blue dots), setting the 330 activity without SHP2 inhibitor as 0%. Data were fit to sigmoidal dose-response curves (green lines). 331 IC 50 s for GS-493 are found in the main text. 332
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